Dna X (SONM) Operating Income (2018 - 2026)

Dna X (SONM) has 9 years of Operating Income data on file, last reported at -$3.6 million in Q1 2026.

• Quarterly Operating Income fell 315.86% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.7 million (down 654.8% YoY) and the FY2025 annual result came in at -$5.4 million, down 74.39% from the prior year.
• Operating Income slipped to -$3.6 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $8.4 million in Q4 2024 to a low of -$7.1 million in Q1 2022.
• A 5-year average of -$1.6 million and a median of -$1.9 million in 2022 frame the typical range for Operating Income.
• The widest YoY moves for Operating Income: up 772.11% in 2024, down 966.13% in 2024.
• Tracing SONM's Operating Income over 5 years: stood at -$1.1 million in 2022, then dropped by 18.51% to -$1.3 million in 2023, then surged by 772.11% to $8.4 million in 2024, then sank by 44.74% to $4.7 million in 2025, then slumped by 177.62% to -$3.6 million in 2026.
• The last three Operating Income figures came in at -$3.6 million (Q1 2026), $4.7 million (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.